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The Risk of Stroke in Patients with Psoriasis
Joel M. Gelfand1,2, Erica D. Dommasch1, Daniel B. Shin1, Rahat S. Azfar1,2, Shanu K. Kurd1, Xingmei Wang2
and Andrea B. Troxel2,3
Psoriasis is a chronic Th-1 and Th-17 inflammatory disease. Chronic inflammation has also been associated with
atherosclerosis and thrombosis. The purpose of this study was to determine the risk of stroke in patients with
psoriasis. We conducted a population-based cohort study of patients seen by general practitioners participating
in the General Practice Research Database in the United Kingdom, 1987–2002. Mild psoriasis was defined as any
patient with a diagnostic code of psoriasis, but no history of systemic therapy. Severe psoriasis was defined as
any patient with a diagnostic code of psoriasis and a history of systemic therapy consistent with severe psoriasis.
The unexposed (control) population was composed of patients with no history of a psoriasis diagnostic code.
When adjusting for major risk factors for stroke, both mild (hazard ratio (HR) 1.06, 95% confidence interval (CI)
1.0–1.1) and severe (1.43, 95% CI 1.1–1.9) psoriasis were independent risk factors for stroke. The excess risk of
stroke attributable to psoriasis in patients with mild and severe disease was 1 in 4,115 per year and 1 in 530 per
year, respectively. Patients with psoriasis, particularly if severe, have an increased risk of stroke that is not
explained by major stroke risk factors identified in routine medical care.
JID JOURNAL CLUB ARTICLE: For questions, answers, and open discussion about this article, please go to http://network.nature.com/group/jidclub
Journal of Investigative Dermatology (2009) 129, 2411–2418; doi:10.1038/jid.2009.112; published online 21 May 2009
INTRODUCTION
Psoriasis is a chronic inflammatory disease of the skin and
joints that affects about 1–3% of the general population
(Gelfand et al., 2005b; Kurd and Gelfand, 2009). It is
associated with impairments in health-related quality of life
even in mild cases, and with excess mortality in severe cases
(Gelfand et al., 2004, 2007). The cause of psoriasis remains
unknown; however, its etiology involves a complex interac-
tion between genetics and environmental exposures. Psor-
iasis is incurable, and once symptoms occur, the disease is
characterized by a chronic course, with spontaneous, long-
term remissions occurring in a minority of patients. Despite
many treatment advances, the majority of patients with
psoriasis, particularly if severe, have ongoing cutaneous
pathology that persists for decades (Gelfand, 2007; Horn
et al., 2007; Nijsten et al., 2007).
Psoriasis was earlier believed to affect only the skin, and in
some patients, the joints; however, recent evidence suggests
that chronic psoriasis may lead to other diseases in which
inflammation is important (Azfar and Gelfand, 2008). For
example, Th-1 chronic inflammation characteristic of the
psoriasis phenotype is also central to the pathophysiology of
other conditions, such as insulin resistance, atherosclerosis,
and plaque rupture, leading to thrombotic events (Hirosumi
et al., 2002; Hansson, 2005). Recent epidemiological studies
support the link between psoriasis and cardiovascular disease
(Gelfand et al., 2006; Ludwig et al., 2007; Balci et al., 2008).
There is a paucity of data examining the risk of stroke in
patients with psoriasis. For example, a recent study found a
small increased risk of stroke in patients with psoriasis (hazard
ratio (HR) 1.12, 95% confidence interval (CI) 1.00–1.25);
however, this study did not make adjustments for confounding
factors or psoriasis severity (Kaye et al., 2008).
Stroke is a major cause of morbidity and mortality (Donnan
et al., 2008). The major common risk factors for stroke include
diabetes, hypertension, and smoking (Donnan et al., 2008),
which also predispose to cardiovascular risk in general. Less
common, but more specific, risk factors for stroke include
transient ischemic attacks and atrial fibrillation (Donnan et al.,
2008). Most strokes (80%) are ischemic in nature, with the
minority of strokes being hemorrhagic (Donnan et al., 2008).
Ischemic and hemorrhagic strokes share similar risk factors
and can have similar clinical presentations. They can be
differentiated on the basis of sophisticated imaging in the
clinical setting, but are often difficult to differentiate in large
population-based epidemiological studies. As with myocardial
infarction, chronic inflammation is thought to play an
important role in the pathogenesis of stroke (Ding et al.,
2008; McColl et al., 2008). The purpose of this study was to
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examine the risk of stroke in a broadly representative,
population-based cohort of patients with psoriasis.
RESULTS
We identified 129,143 patients with mild psoriasis, 3,603
patients with severe psoriasis, and 496,666 and 14,330
matched controls, respectively (Table 1). Mild psoriasis
patients were slightly younger than controls and severe
psoriasis patients were slightly older than controls. Psoriasis
patients, particularly if severe, were more likely to have
established cardiovascular risk factors than patients without
psoriasis. The majority of patients identified as having severe
psoriasis were treated with methotrexate (Table 2).
The incidence of stroke in control subjects and psoriasis
subjects is shown in Table 3. The unadjusted overall risk of
stroke per 1,000 person-years was slightly lower in mild
psoriasis patients (HR 3.7; 95% CI 3.5–3.8) compared with
controls (4.05; 95% CI 4.0–4.1). The unadjusted overall risk
of stroke per 1,000 person-years was higher in severe
psoriasis patients (6.1; 95% CI 4.8–7.6) than in controls
(4.4; 95% CI 3.8–5.0).
When adjusting for age and sex, both mild and severe
psoriasis were associated with an increased risk of stroke
(Table 4, HR 1.07, 95% CI 1.0–1.1, and 1.44, 95% CI
1.1–1.9, respectively). When adjusting for major risk factors
for stroke (age, sex, diabetes, history of stroke or transient
ischemic attack, hyperlipidemia, hypertension, smoking),
both mild (HR 1.06, 95% CI 1.0–1.1) and severe (1.43,
95% CI 1.1, 1.9) psoriasis were independent risk factors for
stroke. On the basis of these analyses, we estimate that each
year there is approximately one excess stroke per 4,115 or
530 mild or severe psoriasis patients, respectively (that is,
attributable risk). Obesity and atrial fibrillation were not
included in the model, as their inclusion did not alter the
association between psoriasis and stroke (see Table 5). In
addition, on the basis of an external adjustment analysis, an
unknown or unmeasured covariate with a prevalence of 20%
in the control group would need to have a prevalence odds
ratio of association with psoriasis of 2.67 and be associated
with stroke with an odds ratio of 4.3 to render the association
between severe psoriasis and stroke null. The results were
robust to numerous sensitivity analyses as shown in Table 5.
DISCUSSION
The results of this study show that patients with severe
psoriasis have a 44% increased risk of stroke, a potentially
devastating comorbidity. The risk of stroke in patients with
psoriasis was not explained by both common and rare major
risk factors for stroke as identified in routine medical practice,
suggesting that psoriasis may be an independent risk factor
for stroke. Patients whom we classified as having mild
psoriasis had a statistically significant increased risk of stroke;
however, this association was very modest and of limited
clinical significance for the individual patient. For example,
on the basis of our data, a patient with mild psoriasis has an
excess risk of stroke attributable to psoriasis of 1 in 4,115 per
year, whereas a patient with severe psoriasis has an excess
risk of stroke attributable to psoriasis of 1 in 530 per year.
The increased risk of stroke persisted in a variety of
sensitivity analyses designed to insure that we were capturing
incident, not prevalent, strokes, and that insured that all
patients were seen regularly, minimizing the risk that
information bias could explain the findings. Furthermore,
the results persisted when excluding patients with psoriatic
arthritis, restricting the severe group to patients treated with
therapy specific to severe psoriasis (for example, oral
retinoids), and when examining the risk based on different
treatments that theoretically could increase (for example,
cyclosporine, oral retinoids) or decrease (for example,
methotrexate) the risk of stroke (Lebwohl and Ali 2001;
Prodanowich et al., 2005). Our findings are in agreement
with recent studies that have found that psoriasis is an
independent risk factor for cardiovascular disease in general
(for example, Myocardial infarction and coronary artery
disease) and cerebrovascular disease in particular (Gelfand
et al., 2006; Ludwig et al., 2007; Balci et al., 2008). Our
study also extends the findings of earlier studies that observed
an association between psoriasis and cerebrovascular disease
or stroke, but did not account for psoriasis severity or
confounding factors (Kaye et al., 2008).
As with all studies, there are important limitations to
consider. In database studies, there remains the possibility for
misclassification of stroke because of coding errors or
misdiagnosis. The overall incidence of stroke in our study
was similar in the two control groups and is similar to rates of
stroke reported using national statistics from England and
Wales (Carroll, 2001). Although several studies have used
General Practice Research Database (GPRD) to evaluate the
epidemiology of stroke, a small validation study showed that,
for 25 patients in the GPRD referred for a diagnostic code of
stroke, there was a confirmation of stroke by the specialist in
64% of cases and a diagnosis of transient ischemic attack in
16% of cases, giving an overall agreement in the opinion of
an acute cerebrovascular diagnosis of 80% (Gibbs et al.,
2001). If misdiagnosis of stroke were present, such errors
would be expected to be non-differential misclassification
and, therefore, would bias our results toward the null.
Furthermore, it is difficult to differentiate between ischemic
and hemorrhagic strokes in large population-based studies of
medical record data, and therefore it cannot be determined
directly how psoriasis influences the risk of various subtypes
of strokes. As the majority of strokes are ischemic in nature,
the results are likely driven by the association of psoriasis and
ischemic stroke. The association between severe psoriasis
and stroke was similar in a sensitivity analysis restricting the
outcome of stroke to those who received therapy consistent
with an ischemic etiology. Another potential limitation of our
study is that we did not examine patients with exclusively
incident (new onset) psoriasis. Therefore, we could not
determine how the duration of psoriasis affects stroke risk,
and it is possible that some bias toward null findings could be
introduced through the depletion of susceptible patients (for
example, some patients with psoriasis would have died from
stroke before being captured in our study population).
Ideally, an inception cohort study could be carried out;
however, in diseases such as psoriasis, which may not come
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Table 1. Characteristics of study groups
Mild group Severe group
Characteristics Control (n=496,666) Psoriasis (n=129,143) Control (n=14,330) Psoriasis (n=3,603)
Sex
Male 198,498 (40.0%) 61,956 (48.0%) 5,783 (40.4%) 1,750 (48.6%)
Female 298,168 (60.0%) 67,187 (52.0%) 8,547 (59.6%) 1,853 (51.4%)
Po0.001 Po0.001
Age (y)
Mean±SD 46.1±19.1 45.1±17.8 49.7±19.3 52.2±16.7
Median (IQR) 43, 30, 61 42, 30, 59 48, 33, 65 52, 39, 66
Po0.001 Po0.001
Wilcoxon test Wilcoxon test
Diabetes mellitus
Yes 22,296 (4.5%) 5,858 (4.5%) 737 (5.1%) 270 (7.5%)
No 474,370 (95.5%) 123,285 (95.5%) 13,593 (94.9%) 3,333 (92.5%)
P=0.470 Po0.001
History of stroke
Yes 7,401 (1.5%) 1,648 (1.3%) 268 (1.9%) 89 (2.5%)
No 489,265 (98.5%) 127,495 (98.7%) 14,062 (98.1%) 3,514 (97.5%)
Po0.001 P=0.023
History of TIA
Yes 5637 (1.1%) 1254 (1.0%) 243 (1.7%) 68 (1.9%)
No 491,029 (98.9%) 127,889 (99.0%) 14,087 (98.3%) 3,535 (98.1%)
Po0.001 P=0.432
History of stroke or TIA
Yes 11,883 (2.4%) 2,655 (2.1%) 450 (3.1%) 140 (3.9%)
No 484,783 (97.6%) 126,488 (97.9%) 13,880 (96.9%) 3,463 (96.1%)
Po0.001 P=0.028
Hyperlipidemia
Yes 22,839 (4.6%) 6,775 (5.2%) 842 (5.9%) 250 (6.9%)
No 473,827 (95.4%) 122,368 (94.8%) 13,488 (94.1%) 3,353 (93.1%)
Po0.001 P=0.019
Hypertension
Yes 88,397 (17.8%) 22,829 (17.7%) 3,049 (21.3%) 858 (23.8%)
No 408,269 (82.2%) 106,314 (82.3%) 11,281 (78.7%) 2,745 (76.2%)
P=0.313 P=0.001
Smoking
Never 383,824 (77.3%) 96,944 (75.1%) 10,465 (73.0%) 2,488 (69.1%)
Current 19,839 (4.0%) 5,866 (4.5%) 755 (5.3%) 241 (6.7%)
Former 93,003 (18.7%) 26,333 (20.4%) 3,110 (21.7%) 874 (24.3%)
Po0.001 Po0.001
BMI
o25 166,470 (53.2%) 40,606 (49.6%) 5,057 (51.2%) 1,025 (42.1%)
X25 & o30 100,551 (32.1%) 27,701 (33.8%) 3,291 (33.3%) 860 (35.4%)
X30 45,977 (14.7%) 13,618 (16.6%) 1,522 (15.4%) 548 (22.5%)
Po0.001 Po0.001
Table 1 Continued on the following page
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to medical attention for many years; it is difficult to validly
identify truly incident (new onset) cases in a medical records
database setting. Furthermore, we did not directly determine
the severity of psoriasis on the basis of the extent of skin disease,
which may introduce misclassification of mild and severe
psoriasis when using therapy as a marker of psoriasis
phenotype. It is likely that our mild psoriasis group contains a
small subset of patients with severe skin disease, as systemic
therapies are used infrequently for psoriasis in the general
population, and that our severe group contains a small subset of
patients with mild skin disease despite the use of systemic
therapy. This misclassification would result in an overestimation
and underestimation of the risk of stroke in the mild and severe
psoriasis patients, respectively. Moreover, the generalizability of
our results to patients with severe psoriasis, who are not treated
with the agents that we used to identify severe disease, needs to
be determined in future studies. Finally, although our study
suggests that psoriasis, particularly if severe, is an independent
risk factor for stroke, it is possible that incomplete measurement
of confounders or unknown confounding factors could explain
some of the observed association. We did not adjust for alcohol
in this analysis as validly measuring alcohol intake in any setting
is challenging, the relationship between alcohol consumption
and stroke is a complex ‘‘J-shaped’’ curve, and the relationship
between stroke and alcohol intake is believed to be mediated by
hypertension (which was adjusted for in our models) (Reynolds
et al., 2003; CDC, 2007). Analyzing our data using an external
adjustment approach suggests that such an unknown or
unmeasured confounder would have to be common in the
general population, and have a strong association with psoriasis
and a stronger association with stroke than the known stroke risk
factors to render our findings null (Greenland, 1996).
This study adds to the growing literature suggesting that
patients with psoriasis, particularly if disease is severe, are at
increased risk of cardiovascular events that is not explained by
traditional risk factors. Clinicians are advised to alert psoriasis
patients, particularly if disease is severe, to have assessment and
treatment of their cardiovascular risk factors as recommended by
current guidelines (Friedewald et al., 2008; Kimball et al., 2008).
More research is necessary to directly determine the mechanisms
by which psoriasis may lead to adverse cardiovascular outcomes,
as well as how psoriasis severity and treatment influence
cardiovascular risk.
METHODS
Study population and data source
We conducted a cohort study using the GPRD, a medical records
database in the United Kingdom that was established for epidemio-
logical research in 1987 (Gelfand et al., 2005a). The GPRD is
representative of the UK population in terms of age, sex, and
geographic distributions. Approximately 5% of the UK population is
represented in the GPRD, and cumulative data are available for over
9 million patients with over 40 million person-years of follow-up
time. In the United Kingdom,499% of patients are registered with a
General practitioner (GP) through the National Health Service,
which coordinates all of the patient’s medical care. Data on
diagnoses and prescriptions are recorded by the GPs as part of the
patient’s electronic medical record. Patients with complex medical
Table 1. Continued
Mild group Severe group
Characteristics Control (n=496,666) Psoriasis (n=129,143) Control (n=14,330) Psoriasis (n=3,603)
Reason for end of study
Death 32,677 (6.6%) 7,302 (5.6%) 790 (5.5%) 297 (8.2%)
End of UTS 353,565 (71.2%) 95,275 (73.8%) 11,247 (78.5%) 2,860 (79.4%)
Transfer out 110,424 (22.2%) 26,566 (20.6%) 2,293 (16.0%) 446 (12.4%)
Po0.001 Po0.001
Atrial fibrillation
Yes 12,861 (2.6%) 3,046 (2.4%) 428 (3.0%) 99 (2.8%)
No 485,486 (97.4%) 126,117 (97.6%) 13,963 (97.0%) 3,505 (97.3%)
Po0.001 P=0.507
BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range, SD, standard deviation; TIA,
transient ischemic attack; UTS, up-to-standard.
Data for BMI were available for 67% of the patients.
Unless noted otherwise, P-values are derived using Fisher exact test.
Table 2. Systemic therapies received by patients with
severe psoriasis (n=3,603)1





Etretinate or acetretin 333 (9.2%)
Hydroxyurea 208 (5.8%)
Mycophenolate mofetil 9 (0.3%)
1Percentages do not add up to 100 because patients could have received
more than one systemic therapy.
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conditions are seen by specialists (at the request of the GP) who may
initiate a new treatment; however, patients are then referred back to
the GP for chronic monitoring as necessary. Certain treatments, such
as PUVA (psoralen plus UVA) and oral retinoids, are restricted to the
dermatologists in the United Kingdom; however, GPs capture these
treatments through their electronic medical record. The GPRD has
been shown to capture information on diagnoses and treatments
from specialists through the GP’s electronic medical record (Jick
et al., 1991, 2003). GPs received specific training and were subject
to inducements and penalties to ensure high-quality data. The data
are also audited for completeness and a practice receives an up-to-
standard (UTS) designation when at least 95% of the relevant
prescriptions and diagnoses are captured electronically. Over 250
peer-reviewed scientific papers have been published using GPRD
data (Gelfand et al., 2005a). The GPRD has also been studied in
numerous validation studies, including those of psoriasis and
cardiovascular disease, to show that it captures these outcomes
accurately (Gelfand et al., 2003, 2005a, 2005b; Neimann et al.,
2006; Huerta et al., 2007).
Time period and age eligibility. Data were used from 1987–2002
for patients who were age X18 at the date their person-time began.
Definition of exposure
We defined mild psoriasis patients as those with a diagnostic code of
psoriasis, but no history of systemic therapy at any time point. Severe
psoriasis patients were defined as those with a diagnostic code of
psoriasis and a history of systemic therapy consistent with severe
psoriasis. Systemic therapy included phototherapy, PUVA, metho-
trexate, azathioprine, cyclosporine, oral retinoids (etretinate, acitre-
tin), hydroxyurea, and mycophenolate mofetil. It is noted that during
the time period that this study was conducted, biological therapies
were not approved for use for psoriasis in the United Kingdom. The
unexposed (control) population was composed of patients with no
history of a psoriasis diagnostic code.
Sampling of exposed and unexposed cohorts
All patients defined as having mild or severe psoriasis (as defined
above), who wereXage 18 at their index date and had at least 1 day
of observation time, were included. For psoriasis patients, the index
date was the first date on or after registration with the practice in
which a psoriasis diagnosis was recorded. For patients with severe
psoriasis, their index date was the first date on or after the first
diagnosis of psoriasis in which the patient received a code for
treatment consistent with severe disease. If psoriasis occurred before
registration, then the registration date was the index date. For
patients without psoriasis, their index date was the date of a medical
record entry that was within 60 days of the psoriasis index date. Up
to four control subjects who were Xage 18 at their index date were
Table 3. Incidence of stroke in patients with psoriasis compared with control patients
Mild group Severe group
Variable Control (n=496,666) Psoriasis (n=129,143) Control (n=14,330) Psoriasis (n=3,603)
Follow-up time (y)
Mean±SD 4.2±3.3 4.4±3.3 3.4±2.7 3.4±2.7
Median (IQR) 3.5 (1.5, 6.6) 3.7 (1.6, 6.9) 2.6 (1.2, 5.0) 2.7 (1.2, 5.0)
Number of person-years 2,108,718 570,814.5 48,248.4 12,222.1
Number of new stroke cases (%) 8,535 (1.72%) 2,100 (1.63%) 212 (1.48%) 74 (2.05%)
Incidence per 1,000 person-years (95% CI) 4.05 (3.96, 4.13) 3.68 (3.52, 3.84) 4.39 (3.82, 5.03) 6.05 (4.76, 7.60)
CI, confidence interval; IQR, interquartile range; SD, standard deviation.
Table 4. Unadjusted and adjusted Cox proportional
hazard regression models of the risk of stroke in
patients mild and severe psoriasis compared with
control patients
Model hazard ratio (95% CI)
Covariate Mild psoriasis Severe psoriasis
Unadjusted analysis
Psoriasis 0.91 (0.86, 0.95) 1.38 (1.05, 1.80)
Adjusted for age and sex
Psoriasis 1.07 (1.02, 1.12) 1.44 (1.10, 1.88)
Age per year 1.089 (1.087, 1.090) 1.09 (1.08, 1.10)
Sex (male) 1.27 (1.22, 1.32) 1.51 (1.20, 1.91)
Primary model (adjusted for major cardiovascular risk factors)1
Psoriasis 1.06 (1.01, 1.11) 1.43 (1.10, 1.87)
Age per year 1.082 (1.081, 1.084) 1.08 (1.07, 1.09)
Diabetes 1.78 (1.69, 1.87) 1.60 (1.16, 2.19)
Hx of Stroke 4.26 (4.01, 4.51) 3.65 (2.57, 5.18)
Hx of TIA 2.01 (1.87, 2.16) 2.05 (1.40, 3.01)
Hyperlipidemia 1.12 (1.04, 1.20) 1.35 (0.92, 1.98)
Hypertension 1.49 (1.43, 1.55) 1.72 (1.35, 2.18)
Sex (male) 1.20 (1.16, 1.25) 1.42 (1.12, 1.80)
Smoking (current vs never) 0.97 (0.89, 1.06) 1.09 (0.71, 1.68)
Smoking (former vs never) 1.10 (1.03, 1.17) 1.24 (0.89, 1.73)
BMI, body mass index; CI, confidence interval; HR, hazard ratio; TIA,
transient ischemic attack.
1BMI was not included in the primary analysis as these data are only
available in about 65% of patients. BMI analyses are shown in Table 5.
Atrial fibrillation was not included in the primary analysis as this is not
a common stroke risk factor. Atrial fibrillation analyses are shown in
Table 5. Interaction terms for sex and age were not statistically significant
(P40.05).
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randomly selected for each psoriasis patient, matched on practice,
date of registration in the practice, and psoriasis index date
(corresponding to a medical record date of the control patient).
The matching on dates occurred as follows: registration: ±90 days
(if registration date X1980, otherwise ±5 years), index date: ±60
days. The purpose of matching on practice, registration, and index
dates was to ensure that patients with and without psoriasis were
evaluated by similar physicians during the same time period to
account for potential variations in medical practice and to allow for
similar degrees of opportunity for GPs to identify medical conditions
in psoriasis and non-psoriasis patients.
Person-time calculation. For mild psoriasis patients, follow-up
started at the latest date when the patient first received a psoriasis
code, registered in the practice, or the practice was deemed UTS. For
severe psoriasis patients, follow-up started at the latest on the date
when the patient could first be defined as having severe psoriasis (for
example, received a treatment code consistent with severe disease),
was registered with the practice, or the practice was deemed UTS.
For unexposed subjects (controls), follow-up started at the latest date
when the patient was registered in the practice, and the practice was
deemed UTS. For all groups, follow-up ended at the earliest date of
developing the outcome of interest (for example, stroke), death, transfer
out of the practice, or end of UTS.
Outcome of interest. The outcome of interest was stroke
occurring after the start date. Stroke was identified using diagnostic
codes (READ or OXMIS) entered by the GP into the medical record.
The use of diagnostic codes to identify stroke has been a well-
accepted methodology in earlier GPRD studies (Gibbs et al., 2001;
Cleary et al., 2004; Nightingale and Farmer, 2004; Souverein et al.,
2004; Mulnier et al., 2006; Weiner et al., 2007) (Tannen et al.,
2006). We defined any stroke code that occurred after the start date
as an incident stroke, whereas any stroke code that occurred on or
before the start date was defined as a prevalent (for example, history
of) stroke.
Covariables of interest. Major epidemiological risk factors for
stroke, including age, sex, hypertension, diabetes, hyperlipidemia,
atrial fibrillation, body mass index, and smoking (current, former,
non), were identified by the presence of diagnostic codes for the
conditions or direct calculation from data in the medical record (for
example, body mass index).
Analysis. The sample size was determined by including the
maximum eligible number of patients with severe psoriasis on the
basis of age criteria. We randomly selected up to four control
subjects per patient with psoriasis, as additional matching yields
minimal increases in statistical power. Data were summarized
descriptively. Dichotomous variables were tested with Fisher’s exact
test and continuous variables were tested with a t-test. We fitted age-
and sex-adjusted Cox models to determine the overall HR of stroke
in psoriasis patients (Cox, 1972). When indicated by an association
of psoriasis with stroke based on the Cox models, we fitted models
with covariates for stroke included (described above) and models
with age and sex interaction terms to determine whether the relative
risk of stroke in psoriasis patients was different on the basis of sex or
age characteristics. The primary model includes major cardiovas-
cular risk factors. We did not include body mass index in the primary
model as it is recorded in only about 65% of patients. Each
dichotomous variable in the model was checked for proportionality
while adjusting for the other covariates in the model by examining
diagnostic log–log plots. A method of external adjustment was used
to determine the degree to which our findings could be explained by
an unknown or unmeasured confounder (Greenland, 1996). Multi-
ple sensitivity analyses were carried out to test the underlying
Table 5. Sensitivity analysis hazard ratio point estimates
Model hazard ratio (95% CI)
Covariate Mild psoriasis Severe psoriasis
Primary analysis 1.06 (1.01, 1.11) 1.43 (1.10, 1.87)
At least 6 months of follow-up (to ensure capture of incident, not prevalent stroke) 1.07 (1.02, 1.13) 1.44 (1.08, 1.93)
Inclusion of patients with at least one GP visit per year 1.05 (1.002, 1.10) 1.40 (1.07, 1.83)
Primary model excluding patients with history of stroke or TIA (to ensure capture
of incident, not prevalent stroke)
1.08 (1.02, 1.14) 1.39 (1.02, 1.89)
Primary model with BMI adjustment 1.03 (0.96, 1.10) 1.43 (1.02, 2.02)
Primary model excluding patients with no BMI captured 1.03 (0.96, 1.10) 1.41 (1.004, 1.99)
Primary model with atrial fibrillation adjustment 1.04 (0.99, 1.09) 1.46 (1.12, 1.91)
Primary model with exclusion of patients with psoriatic arthropathy 1.06 (1.01, 1.11) 1.50 (1.12, 2.00)
Primary model with exclusion of Methotrexate NA 1.49 (1.01, 2.19)
Primary model with exclusion of oral retinoids or cyclosporine NA 1.43 (1.07, 1.92)
Primary model with restriction of severe group to patients who have received a
prescription for an oral retinoid
NA 1.45 (0.78, 2.67)
Primary model with restriction of stroke to patients who received a prescription code for
anti-platelet, anti-coagulant, or thrombolytic therapy within 30 days of the stroke diagnosis.
0.99 (0.91, 1.09) 1.36 (0.80, 2.30)
BMI; body mass index; CI, confidence interval; GP, general practitioner; HR, hazard ratio; NA, not applicable; TIA, transient ischemic attack.
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assumptions of our primary analysis. All analyses were carried out
using STATA 10.0.
Protection of human subjects
This study was approved by the University of Pennsylvania
Institutional Review Board and by the Independent Scientific
Advisory Committee of the Medicines and Healthcare Products
Regulatory Agency of the United Kingdom Department of Health.
The study was conducted in accordance with the Declaration of
Helsinki.
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